We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

In kind

19 June 2008 By Robert Cyran

The drug giant inked an agreement that postpones generic competition to its $12bn cholesterol drug from India s Ranbaxy. The quid pro quo: Ranbaxy can sell another of Pfizer s drugs. This may not be as obviously anticompetitive as a cash payment, but it s close.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)